stoxline Quote Chart Rank Option Currency Glossary
  
Axcella Health Inc. (AXLA)
4.58  0 (0%)    05-13 16:00
Open: 0.36
High: 4.58
Volume: 6,782
  
Pre. Close: 4.58
Low: 0.36
Market Cap: 0(M)
Technical analysis
2024-01-12 4:49:35 PM
Short term     
Mid term     
Targets 6-month :  3.11 1-year :  4.78
Resists First :  2.66 Second :  4.09
Pivot price 0.66
Supports First :  0.34 Second :  0.28
MAs MA(5) :  0.45 MA(20) :  0.74
MA(100) :  6.65 MA(250) :  8.8
MACD MACD :  -0.9 Signal :  -1.1
%K %D K(14,3) :  13.1 D(3) :  15.6
RSI RSI(14): 20.6
52-week High :  41.25 Low :  0.34
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AXLA ] has closed above bottom band by 15.1%. Bollinger Bands are 91.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.51 - 0.51 0.51 - 0.52
Low: 0.35 - 0.36 0.36 - 0.36
Close: 0.4 - 0.4 0.4 - 0.4
Company Description

Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

Headline News

Wed, 22 May 2024
Are Medical Stocks Lagging Clover Health Investments (CLOV) This Year? - Yahoo New Zealand News

Sun, 05 May 2024
Down 24.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Axcella Health Inc. (AXLA) - Yahoo Movies UK

Sat, 04 May 2024
Are Medical Stocks Lagging Axcella Health (AXLA) This Year? - Yahoo Lifestyle UK

Fri, 08 Dec 2023
Axcella Health Becomes the Latest Flagship Company to Close its Doors - BioSpace

Tue, 19 Sep 2023
Axcella Health (NASDAQ: AXLA) to jump 2,500% at the open - this is purely nominal - Dhaka Tribune

Thu, 14 Sep 2023
Short squeeze alert for September 14th: Two stocks that could see remarkable gains - Finbold - Finance in Bold

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 3 (M)
Held by Insiders 1.07e+006 (%)
Held by Institutions 15.8 (%)
Shares Short 116 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -4.13e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -87.7 %
Return on Equity (ttm) -1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 649.42
EBITDA (p.s.) 0
Qtrly Earnings Growth -18.3 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -43 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0.3
Stock Dividends
Dividend 0
Forward Dividend 78180
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android